Trio of first-day pops may bode well for biotech IPO window

Three late-stage IPOs signaled a positive change for the biotech IPO market with upsized offerings, and, more importantly, positive aftermarket performance. 

Investors may have already been willing to look at more risky assets given expectations about an upcoming interest rate cut, with the Federal Reserve meeting next week. But for the IPO market to improve, all three deals will need to continue to trade positively in the aftermarket...